Promoter holding
64.27%
BB
Biocon Biologics Limited - Due diligence report
A 360° intelligence report on Bbil: trust score, financial health, credit view, compliance, directors, growth and distress signals - generat…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Bbil — 360° Intelligence Report
Generated from MCA filings & public records88/100
Trust Score
Low Risk
Bbil is assessed as Low Risk with a Trust Score of 88/100. Bbil is an active public limited indian non-government company incorporated in 2016, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Biocon Biologics Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
88/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
78/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
80/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
- Moderate gearing (D/E 38%).
- Profitable - internal accruals available.
- Externally credit-rated (AA+).
Charges position: 2 open (9,543.66 cr) · 6 satisfied (18,987.20 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 5 | 48.0 cr |
| The Hongkong And Shanghai Banking Corporation Limited | 2 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
Compliance Score: 78/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 2 court forum(s).
- Delayed payments to MSME suppliers disclosed (2226 disclosure(s)).
- 19 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 80/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| BOBBY KANUBHAI PARIKH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KIRAN MAZUMDAR SHAW | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DANIEL MARK BRADBURY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJIV MALIK | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PETER BARON PIOT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHREEHAS PRADEEP TAMBE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHREEHAS PRADEEP TAMBE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Mr. Kedar Upadhye | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NIVRUTI RAI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARUN SURESH CHANDAVARKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| THOMAS JASON ROBERTS | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Akhilesh Nand | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 12 directors on the board.
- No disqualified or deactivated DINs.
- 4 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Biocon Limited
Subsidiaries
5
Group entities
6
Capital events
15 allotment(s) · 7 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Biocon Biologics Uk Limited | Subsidiary Company | 74.00% |
| Biocon Biologics Global Plc | Subsidiary Company | 74.00% |
| Biocon Biologics Do Brasil Ltda. | Subsidiary Company | 74.00% |
| Lemnservice Fichtel Srl | Subsidiary Company | 74.00% |
| Biocon Biologics France S.a.s | Subsidiary Company | 74.00% |
| Biocon Limited | Holding Company | 74.00% |
Key managerial personnel: KIRAN MAZUMDAR SHAW (Whole-time director) · SHREEHAS PRADEEP TAMBE (CEO) · SHREEHAS PRADEEP TAMBE (CEO) · Mr. Kedar Upadhye (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Net margin improved to 0.86.
Operating for 10+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
2 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 160.94 cr.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence85/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment84/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 2 open charge(s) of 9,543.66 cr already registered.
- Compliance record supports lending.
Investor view93/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events25 Jul 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
09 Jan 2025
Charge satisfied
Others
07 Jan 2025
Charge satisfied
The Hongkong And Shanghai Banking Corporation Limited
06 Jan 2025
Charge satisfied
Others
17 Dec 2024
Charge satisfied
The Hongkong And Shanghai Banking Corporation Limited
09 Dec 2024
Charge created
Others - 2,734.90 cr
22 Nov 2024
Charge created
Others - 6,808.76 cr
21 Aug 2024
Director appointed
Akhilesh Nand (Company Secretary)
31 Jul 2024
Director ceased
DEEPIKA SRIVASTAVA
07 Jun 2024
Director ceased
JOHN RUSSELL FOTHERINGHAM WALLS
22 Apr 2024
Director ceased
Nicholas Robert Haggar
26 Feb 2024
Charge satisfied
Others
31 Oct 2023
Director ceased
CHINAPPA MUCKATIRA BHEMAIAH
31 Mar 2023
Share transfer (FY 2023)
155300.00000000 shares to Biocon Limited
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
12 active director(s) / partner(s); board looks stable and experienced.
19 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 5 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of AA+ from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 15 security allotment(s) - amounts available in the full report.
9 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Finolex Pipes | L40108PN1981PLC024153 | District Pune, Maharashtra, India |
| Natcopharma | L24230TG1981PLC003201 | Hyderabad, Telangana, India |
| Ajanta Pharma | L24230MH1979PLC022059 | Mumbai, Maharashtra, India |
| Emcure | L24231PN1981PLC024251 | Pune City, Maharashtra, India |
| Himadri | L27106WB1987PLC042756 | Kolkata, West Bengal, India |
| Tatachemicals | L24239MH1939PLC002893 | Mumbai, Maharashtra, India |
| Atul | L99999GJ1975PLC002859 | Ahmedabad, Gujarat, India |
| Lauruslabs | L24239AP2005PLC047518 | Anakapalle, Andhra Pradesh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Bbil before audits and certifications: compliance score 78/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Bbil: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Bbil - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 88/100, distress signals and MSME payment-delay disclosures - know whether Bbil pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Bbil - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Bbil an active company?
Bbil has MCA status “Active” with a compliance score of 78/100 (Low Risk).
Is Bbil financially healthy?
Bbil has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Bbil?
Its overall Trust Score is 88/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Bbil?
The ultimate holding entity is Biocon Limited. 12 active director(s) are on record.
Does Bbil have loans or charges against its assets?
2 open charge(s) are registered against its assets, and 6 earlier charge(s) stand satisfied.
Is Bbil up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 78/100 (Low Risk).
Is it risky to lend to Bbil?
Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
